Search 
Friday, July 03, 2009 ..:: Clinical Trials ::.. Register  Login
 Clinical Trials Minimize
 Print   
 Search Trials Minimize
 Print   
 Archives Minimize
Study Number:

Search
  
 Genitourinary Minimize
Category: Genitourinary Created: 1/2/2007 11:31 AM
Genitourinary
Bladder (100892)
Sponsor: Genentech (AVF 3312)

 		By Genitourinary on 7/2/2009 4:00 AM
A Phase II Study of Neo-adjuvant Cisplatin, Gemcitabine, & Avastin, followed by Radical Cystectomy for Patients with Muscle invasive, Resectable, Non-Metastatic Transitional Cell carcinoma (TCC) of the Bladder

HIPAA Authorization
Informed Consent - Intervention
Protocol
More...
Bladder (100919)
Sponsor: NCI (100919)

 		By Genitourinary on 7/2/2009 4:00 AM
The Role of Thromboxane A2 in Bladder Cancer

None Available
More...
Bladder (101267)
Sponsor: Sanofi-Aventis (EFC 6668)

 		By Genitourinary on 7/2/2009 4:00 AM
Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer

HIPAA Authorization
Informed Consent
Protocol
More...
Bladder (101278)
Sponsor: Southeastern Clinical and Translational Research I (101278)

 		By Genitourinary on 7/2/2009 4:00 AM
Use of Exfoliated Cells in Urine for Detection of Cancer and Prediction of Treatment susceptibility

None Available
More...
Bladder (101301)
Sponsor: Spectrum Pharmaceutical,Inc (SPI-612)

 		By Genitourinary on 7/2/2009 4:00 AM
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer.

Protocol
More...
Bladder (101329)
Sponsor: RTOG (0712)

 		By Genitourinary on 7/2/2009 4:00 AM
A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Selective Bladder Preservation And Gemcitabine/Cisplatin Adjuvant Chemotherapy

HIPAA Authorization
Informed Consent
Protocol
More...
Kidney (101219)
Sponsor: MUSC (101219)

 		By Genitourinary on 7/2/2009 4:00 AM
Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma

HIPAA Authorization
Informed Consent
Protocol
More...
Kidney (101251)
Sponsor: Pfizer (A4061032)

 		By Genitourinary on 7/2/2009 4:00 AM
AXITINIB (AG-013736) As Second Line Therapy For Metastatic Renal Cell Cancer: Axis Trial

HIPAA Authorization
Informed Consent
Protocol
More...
Kidney (101268)
Sponsor: GlaxoSmithKline (VEG108844)

 		By Genitourinary on 7/2/2009 4:00 AM
A Study Pazopanib Versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

HIPAA Authorization
Informed Consent
Informed Consent #2-Intervention
Protocol
More...
Kidney (101334)
Sponsor: Amgen (20080579)

 		By Genitourinary on 7/2/2009 4:00 AM
Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma

HIPAA Authorization
Informed Consent
Informed Consent #2-Intervention
Protocol
More...
Prostate (100783)
Sponsor: MUSC (100783)

 		By Genitourinary on 7/2/2009 4:00 AM
PHASE I TRIAL OF CONCURRENT TAXOTERE WITH RADIATION THERAPY AND HORMONAL THERAPY FOR CLINICALLY LOCALIZED HIGH RISK PROSTATE CANCER

HIPAA Authorization
Informed Consent - Intervention
Protocol
More...
Prostate (100822)
Sponsor: MUSC (03-1218; i34102-033)

 		By Genitourinary on 7/2/2009 4:00 AM
VELCADE (bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer

HIPAA Authorization
Informed Consent - Intervention
Protocol
More...
Prostate (101121)
Sponsor: Cancer Treatment Research Foundation (101121)

 		By Genitourinary on 7/2/2009 4:00 AM
A Study of Vitamin D in Prostate Cancer

None Available
More...
Prostate (101137)
Sponsor: Unviersity of CA-Irvine (CA180-0097)

 		By Genitourinary on 7/2/2009 4:00 AM
A Phase II Trial Of Dasatinib(Sprycel®) In Subjects With Hormonerefractory Prostate Cancer, Previously Treated With Chemotherapy

HIPAA Authorization
Informed Consent
Protocol
More...
Prostate (101165)
Sponsor: AstraZeneca (D4320C00033)

 		By Genitourinary on 7/2/2009 4:00 AM
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancer

HIPAA Authorization
HIPAA Authorization - MUSC
HIPAA-Volunteer
Informed Consent
Informed Consent #2-Intervention
More...
Prostate (101212)
Sponsor: MUSC (101212)

 		By Genitourinary on 7/2/2009 4:00 AM
SNP Profile of Radiosensitivity-relevant Genes and Adverse Radiotherapy Reactions in African-American Prostate Cancer Patients

None Available
More...
Prostate (101217)
Sponsor: RTOG (0534)

 		By Genitourinary on 7/2/2009 4:00 AM
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Sport) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy

HIPAA Authorization - VA
Informed Consent
Informed Consent - VA
Protocol
More...
Prostate (101242)
Sponsor: SWOG (S0421)

 		By Genitourinary on 7/2/2009 4:00 AM
Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer.

HIPAA Authorization
Informed Consent
Protocol
More...
 Print   
Copyright 2007 by Hollings Cancer Center   Terms Of Use  Privacy Statement